Illumina Files Patent Infringement Suit in Switzerland against Genoma SA for Infringement of NIPT Patents
April 21 2016 - 4:05PM
Business Wire
Illumina, Inc. (NASDAQ: ILMN) today announced that it, and its
wholly owned subsidiary, Verinata Health, Inc. (together
“Illumina”), filed a patent infringement suit against Genoma SA in
the Federal Patent Court in Switzerland. Illumina is seeking all
available remedies, including damages and injunctive relief.
The patents asserted are European Patent (CH) 2 183 693 B1,
European Patent (CH) 0 994 963 B2, European Patent (CH) 1 981 995
B1, and European Patent (CH) 2 514 842. The patents are directed to
using cell-free fetal DNA for non-invasive prenatal testing
(NIPT).
The suit accuses Genoma’s Tranquility® NIPT testing service,
including its use of next-generation sequencing to analyze
cell-free DNA from a sample of maternal blood. Genoma’s testing
facility in Switzerland also services samples collected from its
other labs, including those located in Spain and Italy.
“We will continue to monitor activities in the NIPT field and
file suits where appropriate to protect our substantial investments
in this technology covered by our intellectual property,” said
Charles Dadswell, Senior Vice President and General Counsel for
Illumina.
The Tranquility NIPT service uses the IONA® Test sold by
Premaitha Health plc. Illumina previously filed separate suits
against Premaitha in the United Kingdom for sale of the IONA
Test.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160421006636/en/
Illumina, Inc.Investors:Rebecca
Chambers858-255-5243rchambers@illumina.comorMedia:Jennifer
Temple858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024